Alessandro Romani

Vice President and Head of European Equity Derivatives Products Nasdaq

Alessandro Romani is a Vice President and Head of European Equity Derivatives Products. Responsible for the P/L and the growth strategy for the Nordic equity and index derivatives markets; he leads a highly motivated team of product/project management and derivatives sales support responsibilities. Alessandro has been with Nasdaq since the merger and joined OMX Technology in 2001 covering various positions such as a Technical Account Manager, Business Requirement Analyst and Project Manager. He then moved to the Nasdaq Stockholm Exchange covering various roles as a product developer and project manager for the cash-equity and equity derivatives markets in the Nordic region. He holds a Master of Science in Aeronautical Engineering from Universita’ La Sapienza in Rome (Italy)

Day 1 | 14th May

2:15 PM Market Structure Panel: Navigating market structure complexities: What are the latest market structure and product developments that will help drive interoperability and improve ease of equity derivatives trading?

The US has seen huge growth in derivatives volumes and retail participation in recent years, whilst the European market has remained flat. This is attributed to the lack of retail investor education, and a fragmented market structure with siloed liquidity and clearing models, creating a more complex and costly trading environment. The speakers will look to unpack solutions and ways to improve the current siloed model to lower the barrier to entry and to encourage greater participation, as well as product trends and the migration from OTC to listed.

How do the EU and US market models differ, and can Europe achieve more competition whilst removing venue and clearing silos?
What effort is being made to address the siloed liquidity and clearing model to bring more interoperability to the market?
Examining the product complexities in Europe, and how products have different tax treatments
How are liquidity dynamics shifting in OTC vs listed derivatives, and what are the benefits and disadvantaged to both?
Are we seeing a greater push from OTC to listed due to regulation and balance sheet limitations, and what new innovative listed products are being developed as a result?

Check out the incredible speaker line-up to see who will be joining Alessandro.

Download The Latest Agenda